

KEEPING KIDS IN TUNE

Fennec Pharmaceuticals is a biotechnology company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced chemotherapy ototoxicity (hearing loss) in pediatric patients. Cisplatin, a widely-used chemotherapy agent, can cause irreversible and permanent hearing loss in children.



INVESTMENT HIGHLIGHTS

US Orphan Drug Designation

(7.5 years market exclusivity).

- Potential for 10 years of European market exclusivity for pediatric use.

Completed enrollment of two Phase 3 trials.

Proof of concept COG Phase 3 trial achieved primary endpoint for hearing

- Achieved primary efficacy endpoint of hearing loss protection, $p=0.004$.

SIOPEL 6 Phase 3 trial reported no difference in Event Free Survival and Overall Survival at 2 years for Cisplatin vs. Cisplatin + STS with no evidence of tumor protection.

- Efficacy results (primary endpoint of hearing loss) expected in Q4 2017 when all children have reached 3.5 years of age.
- The interim results of the first 68 were encouraging.

Significant unmet medical need with no approved treatment on market or in development.

Well positioned to initiate discussions with US & European regulators once hearing data is available from SIOPEL 6.

ABOUT US

| | |
|---------------------------|--------------------|
| TSX | FRX |
| OTCQB | FENCF |
| Recent Market Price | USD \$4.4 |
| Shares Outstanding | 15.6 |
| Cash* | USD \$10.8M |
| Cash Runway | Q4 2018 |
| Debt | \$0 |

*March 31st, 2017 (pro forma June 2017 financing)

INSTITUTIONAL OWNERSHIP

Southpoint Capital – 25%
Leadiant Bio (Sigma Tau) – 19%
Manchester Management – 13%
683 Capital – 6%

Varana Capital – 5%
venBio Select Advisor – 5%
Sonic Fund – 2%
Acuta Capital – 2%

MARKET OPPORTUNITY

In the U.S. and Europe it is estimated that over 7,000 children are diagnosed each year with cancers that may receive platinum based chemotherapy. These tumors have generally good prognosis with survival rates of greater than 80%, further emphasizing the importance of quality of life after treatment is completed. The incidence of hearing loss in these children is approximately 60%, with many requiring lifelong hearing aids and technically difficult and sub-optimal cochlear (inner ear) implants. Infants and young children at critical stages of development with even mild hearing loss lack speech language development and literacy, while older children and adolescents

lack social-emotional development and educational achievement. There is currently no established preventive agent for ototoxicity on the market.

STS has been studied by cooperative groups in two Phase 3 clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. Both studies are closed to recruitment. The COG ACCL0431 protocol enrolled one of five childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including newly diagnosed hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma, and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.

BOARD OF DIRECTORS

DR. KHALID ISLAM | *Chairman of Board*
 Chairman & CEO at Gentium S.p.A. Sold to Jazz Pharma for \$1 billion.

DR. MARCO BRUGHERA | *Director, CEO & Global Head of Leadiant BioSciences Ltd.*
 Previously successfully outlicensed Defibrotide US rights to Jazz Pharma to Baxalta for \$1 billion.

ROSTY RAYKOV | *CEO & Director*

ADRIAN HAIGH | *Director.* Currently SVP & GM at PTC Therapeutics. Previously COO at Gentium S.p.A. Sold to Jazz Pharma for \$1 billion.

CHRIS RALLIS | *Director.* Previously President & COO of Triangle Pharmaceuticals. Sold to Gilead for \$500 million.